학술논문
Effect of gonadotropin-releasing hormone analogue on final adult height among Jordanian children with precocious puberty
Document Type
Report
Source
Saudi Medical Journal. November 2017, Vol. 38 Issue 11, p1101, 7 p.
Subject
Language
English
ISSN
0379-5284
Abstract
Precocious puberty is defined as the development of secondary sexual characteristics before the age of 8 years in females and 9 years in males. (1,2) Precocious puberty can be either [...]
[phrase omitted] Objectives: To study the effect of gonadotropin-releasing hormone analogue (GnRHa) on final adult height (FAH) among Jordanian children with central precocious puberty (CPP). Methods: It is a retrospective historical cohort study. We assessed the FAH and height gain in 43 children with CPP (39 females and 4 males) who received GnRHa and 13 children with CPP (11 females and 2 males) who did not receive GnRHa and achieved FAH between 2004 and 2014. Final adult height was compared to target height (TH) and mid- parental height (MPH) in both groups. Results: In GnRHa treated females, the FAH was 158.5 [+ or -] 6.6 cm compared to 151.2 [+ or -] 8.4 cm in the untreated females (p=0.004). Height gain was 2.9 [+ or -] 8.5 cm in the treated females compared to -3.8 [+ or -] 7.7 cm in the untreated group (p=0.022). In GnRHa treated females, FAH was found to be closer to TH (p=0.01) and MPH (p=0.01) in comparison to untreated females. Conclusion: Gonadotropin-releasing hormone analogue is effective in increasing FAH in Jordanian children with CPP, particularly those with advanced bone age. doi: 10.15537/smj.2017.11.21187
[phrase omitted] Objectives: To study the effect of gonadotropin-releasing hormone analogue (GnRHa) on final adult height (FAH) among Jordanian children with central precocious puberty (CPP). Methods: It is a retrospective historical cohort study. We assessed the FAH and height gain in 43 children with CPP (39 females and 4 males) who received GnRHa and 13 children with CPP (11 females and 2 males) who did not receive GnRHa and achieved FAH between 2004 and 2014. Final adult height was compared to target height (TH) and mid- parental height (MPH) in both groups. Results: In GnRHa treated females, the FAH was 158.5 [+ or -] 6.6 cm compared to 151.2 [+ or -] 8.4 cm in the untreated females (p=0.004). Height gain was 2.9 [+ or -] 8.5 cm in the treated females compared to -3.8 [+ or -] 7.7 cm in the untreated group (p=0.022). In GnRHa treated females, FAH was found to be closer to TH (p=0.01) and MPH (p=0.01) in comparison to untreated females. Conclusion: Gonadotropin-releasing hormone analogue is effective in increasing FAH in Jordanian children with CPP, particularly those with advanced bone age. doi: 10.15537/smj.2017.11.21187